Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tadaaki Yamada

Showing results (41-50 of 228) with videos related to

Pageof 23
Sort By:
International Journal of Clinical Oncology|October 27, 2009
Combined chemotherapy with carboplatin plus irinotecan showed favorable efficacy in a patient with relapsed small cell carcinoma of the prostate complicated with meningeal carcinomatosisTadaaki Yamada, Koushiro Ohtsubo, Hisatsugu Mouri, et al.
BMC Pulmonary Medicine|December 14, 2018
Pulmonary carcinosarcoma showing an obvious response to pazopanib: a case reportAzusa Tanimoto, Shinji Takeuchi, Hiroshi Kotani, et al.
Nihon Kokyuki Gakkai Zasshi = the Journal of the Japanese Respiratory Society|June 23, 2005
[Spinal cord metastases in lung cancer: a clinical review of four cases]Hiroomi Kuwahara, Tadaaki Yamada, Tatsuya Yuba, et al.
Cancers|March 2, 2019
Nicotine Induces Resistance to Erlotinib Therapy in Non-Small-Cell Lung Cancer Cells Treated with Serum from Human PatientsTatsuya Imabayashi, Junji Uchino, Hisayuki Osoreda, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|August 19, 2010
[Combined chemotherapy with cisplatin plus vinorelbine showed efficacy in a case of metastatic primary cutaneous adenoid cystic carcinoma]Tadaaki Yamada, Hisatsugu Mouri, Kouji Izumi, et al.
International Journal of Cancer|January 16, 2013
The novel phosphoinositide 3-kinase-mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of epidermal growth factor receptor mutant lung cancer cells triggered by hepatocyte growth factorTakako Sano, Shinji Takeuchi, Takayuki Nakagawa, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|January 12, 2013
[Efficacy of low-dose erlotinib against gefitinib-induced hepatotoxicity in a patient with lung adenocarcinoma harboring EGFR mutations]Hironori Kitade, Tadaaki Yamada, Saya Igarashi, et al.
Internal Medicine (Tokyo, Japan)|June 7, 2021
Late-onset Pleural and Pericardial Effusion as Immune-related Adverse Events after 94 Cycles of NivolumabRyo Sawada, Yohei Matsui, Junji Uchino, et al.
Journal of Diabetes Investigation|January 28, 2016
Efficacy and safety of 40 mg or 60 mg duloxetine in Japanese adults with diabetic neuropathic pain: Results from a randomized, 52-week, open-label studyHitoshi Yasuda, Nigishi Hotta, Masato Kasuga, et al.
Journal of Clinical Medicine|July 3, 2020
Endocrinopathies Associated with Immune Checkpoint Inhibitor Cancer Treatment: A ReviewNaoko Okura, Mai Asano, Junji Uchino, et al.
Pageof 23

Showing results (41-50 of 228) with videos related to

Sort By:
Pageof 23
International Journal of Clinical Oncology|October 27, 2009
Combined chemotherapy with carboplatin plus irinotecan showed favorable efficacy in a patient with relapsed small cell carcinoma of the prostate complicated with meningeal carcinomatosisTadaaki Yamada, Koushiro Ohtsubo, Hisatsugu Mouri, et al.
BMC Pulmonary Medicine|December 14, 2018
Pulmonary carcinosarcoma showing an obvious response to pazopanib: a case reportAzusa Tanimoto, Shinji Takeuchi, Hiroshi Kotani, et al.
Nihon Kokyuki Gakkai Zasshi = the Journal of the Japanese Respiratory Society|June 23, 2005
[Spinal cord metastases in lung cancer: a clinical review of four cases]Hiroomi Kuwahara, Tadaaki Yamada, Tatsuya Yuba, et al.
Cancers|March 2, 2019
Nicotine Induces Resistance to Erlotinib Therapy in Non-Small-Cell Lung Cancer Cells Treated with Serum from Human PatientsTatsuya Imabayashi, Junji Uchino, Hisayuki Osoreda, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|August 19, 2010
[Combined chemotherapy with cisplatin plus vinorelbine showed efficacy in a case of metastatic primary cutaneous adenoid cystic carcinoma]Tadaaki Yamada, Hisatsugu Mouri, Kouji Izumi, et al.
International Journal of Cancer|January 16, 2013
The novel phosphoinositide 3-kinase-mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of epidermal growth factor receptor mutant lung cancer cells triggered by hepatocyte growth factorTakako Sano, Shinji Takeuchi, Takayuki Nakagawa, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|January 12, 2013
[Efficacy of low-dose erlotinib against gefitinib-induced hepatotoxicity in a patient with lung adenocarcinoma harboring EGFR mutations]Hironori Kitade, Tadaaki Yamada, Saya Igarashi, et al.
Internal Medicine (Tokyo, Japan)|June 7, 2021
Late-onset Pleural and Pericardial Effusion as Immune-related Adverse Events after 94 Cycles of NivolumabRyo Sawada, Yohei Matsui, Junji Uchino, et al.
Journal of Diabetes Investigation|January 28, 2016
Efficacy and safety of 40 mg or 60 mg duloxetine in Japanese adults with diabetic neuropathic pain: Results from a randomized, 52-week, open-label studyHitoshi Yasuda, Nigishi Hotta, Masato Kasuga, et al.
Journal of Clinical Medicine|July 3, 2020
Endocrinopathies Associated with Immune Checkpoint Inhibitor Cancer Treatment: A ReviewNaoko Okura, Mai Asano, Junji Uchino, et al.
Pageof 23